[HTML][HTML] Circulating biomarkers for early detection and clinical management of colorectal cancer

M Marcuello, V Vymetalkova, RPL Neves… - Molecular Aspects of …, 2019 - Elsevier
New non-invasive approaches that can complement and improve on current strategies for
colorectal cancer (CRC) screening and management are urgently needed. A growing …

Accessing genetic information with liquid biopsies

X Cai, F Janku, Q Zhan, JB Fan - Trends in Genetics, 2015 - cell.com
Recent scientific advances in understanding circulating tumor cells, cell-free DNA/RNA, and
exosomes in blood have laid a solid foundation for the development of routine molecular …

Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer

Y Lu, J Xue, T Deng, X Zhou, K Yu, L Deng, M Huang… - Nature medicine, 2020 - nature.com
Clustered regularly interspaced short palindromic repeats (CRISPR)–Cas9 editing of
immune checkpoint genes could improve the efficacy of T cell therapy, but the first necessary …

Perioperative dynamic changes in circulating tumor DNA in patients with lung cancer (DYNAMIC)

K Chen, H Zhao, Y Shi, F Yang, LT Wang, G Kang… - Clinical Cancer …, 2019 - AACR
Purpose: No study has investigated the precise perioperative dynamic changes in
circulating tumor DNA (ctDNA) in any patients with early-stage cancer. This study …

Circulating tumor DNA as a prognostic biomarker in localized non-small cell lung cancer

M Peng, Q Huang, W Yin, S Tan, C Chen, W Liu… - Frontiers in …, 2020 - frontiersin.org
Background Routine clinical surveillance involves serial radiographic imaging following
radical surgery in localized non-small cell lung cancer (NSCLC). However, such …

Non-invasive prenatal diagnosis (NIPD): how analysis of cell-free DNA in maternal plasma has changed prenatal diagnosis for monogenic disorders

B Hanson, E Scotchman, LS Chitty… - Clinical …, 2022 - portlandpress.com
Cell-free fetal DNA (cffDNA) is released into the maternal circulation from trophoblastic cells
during pregnancy, is detectable from 4 weeks and is representative of the entire fetal …

Circulating cell free tumor DNA detection as a routine tool for lung cancer patient management

JA Vendrell, FT Mau-Them, B Béganton… - International journal of …, 2017 - mdpi.com
Circulating tumoral DNA (ctDNA), commonly named “liquid biopsy”, has emerged as a new
promising noninvasive tool to detect biomarker in several cancers including lung cancer …

Delivering an accredited non‐invasive prenatal diagnosis service for monogenic disorders and recommendations for best practice

LA Jenkins, ZC Deans, C Lewis, S Allen - Prenatal Diagnosis, 2018 - Wiley Online Library
The identification of cell‐free fetal DNA circulating in maternal blood combined with
technological developments, in particular next‐generation sequencing, is enabling the …

Tracking neoantigens by personalized circulating tumor DNA sequencing during checkpoint blockade immunotherapy in non‐small cell lung cancer

Q Jia, L Chiu, S Wu, J Bai, L Peng, L Zheng… - Advanced …, 2020 - Wiley Online Library
The evolutionary dynamics of tumor‐associated neoantigens carry information about drug
sensitivity and resistance to the immune checkpoint blockade (ICB). However, the spectrum …

The landscape of cell-free HBV integrations and mutations in cirrhosis and hepatocellular carcinoma patients

B Zheng, XL Liu, R Fan, J Bai, H Wen, LT Du… - Clinical Cancer …, 2021 - AACR
Purpose: Intratumoral hepatitis B virus (HBV) integrations and mutations are related to
hepatocellular carcinoma (HCC) progression. Circulating cell-free DNA (cfDNA) has shown …